Cancer metabolism is based on the premise that cancer cells alter glucose and glutamine metabolism in order to synthesize lipids, nucleotides, fatty acids, and proteins, which aids in cancer cell growth. It prevents the citric acid cycle, glucose, mitochondrial respiration, and glutamine consumption. In the near future, restricted options for cancer metabolism focused therapies are expected to provide opportunities for the development of novel cancer metabolism-based therapeutics. The market for cancer metabolism-based medicines is anticipated to expand as a result of the possibility for the development of novel treatments to combat a variety of cancer types by targeting cancer metabolism. The market for cancer metabolism-based medicines is projected to grow as a result of the increased cancer incidence. Additionally, more strategic partnerships between leading companies in the market for Cancer Metabolism Based Therapeutics are anticipated to boost their product portfolios and market share throughout the forecast period.
Major Players in the Cancer Metabolism Based Therapeutics Industry:
1. Calithera Biosciences, Inc.
Calithera Biosciences, Inc. was founded in 2010 and headquartered in California, the US. It operates in other countries also. Calithera Biosciences, Inc. stated in May 2023 that it will hold a special meeting of stockholders in June 2023 (the "Special Meeting") to approve the Company's Plan of Complete Liquidation and Dissolution (the "Plan of Dissolution"). The Company declared its intention to begin an orderly wind down of its company and operations in January 2023.
2. Celgene Corporation
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. It was founded in 1986 and headquartered in New Jersey, U.S. It operates in over 50 countries around the world.
3. Agios Pharmaceutical
Agios Pharmaceutical is a public American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. It was founded in 2008 and headquartered in Massachusetts, United States. It operates in the United States. Agios will focus on discovering and commercializing novel therapies for genetically specified disorders beginning in December 2020, and will sell its oncology business to Servier for up to $2 billion plus royalties. Agios will devote all of its resources on developing Mitapivat as a potential treatment for three initial hemolytic anemias, as well as building on its technical expertise in cellular metabolism and PK activation, in order to accelerate and expand its genetically specified disease portfolio.
4. Rafael pharmaceuticals
Rafael pharmaceuticals was founded in 2002 and headquartered in New Jersey, United States. It operates in across more than 60 sites in countries including the United States, Canada, Europe, India, South Korea and Australia. Rafael Holdings announces a strategic combination with Rafael Pharmaceuticals in June 2021 to build a specialized late-stage Clinical Oncology Company.
5. 3-V Biosciences
3-V Biosciences was founded in 2007 and headquartered in California, United States. It operates globally. At the AACR Metabolism and Cancer Conference in September 2019, 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, was pleased to present new data from its lead program (TVB-2640), a first-in-class fatty acid synthase (FASN) inhibitor.
6. AstraZeneca
AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company. It was founded in 1999 and headquartered in England, UK. It operates in over 100 countries. AstraZeneca expands its pipeline and showcases advancements in immuno-oncology, ADCs, cell therapy, and epigenetics at AACR in April 2023.
Definition: Cancer metabolism refers to the alterations in cellular metabolism pathways that are evident in cancer cells compared with most normal tissue cells.
